These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 33992097)

  • 21. Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.
    Mu Y; Hao X; Xing P; Hu X; Wang Y; Li T; Zhang J; Xu Z; Li J
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2427-2433. PubMed ID: 32385709
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines.
    La Monica S; Cretella D; Bonelli M; Fumarola C; Cavazzoni A; Digiacomo G; Flammini L; Barocelli E; Minari R; Naldi N; Petronini PG; Tiseo M; Alfieri R
    J Exp Clin Cancer Res; 2017 Dec; 36(1):174. PubMed ID: 29202823
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.
    Leonetti A; Sharma S; Minari R; Perego P; Giovannetti E; Tiseo M
    Br J Cancer; 2019 Oct; 121(9):725-737. PubMed ID: 31564718
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
    Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M
    Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of almonertinib on the proliferation, invasion, and migration in non-small cell lung cancer cells.
    Zhang Y; Zhang Y; Niu W; Ge X; Li X; Fan F; Li S; Liu H
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Oct; 46(10):1045-1053. PubMed ID: 34911833
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib.
    Chen Z; Yu D; Owonikoko TK; Ramalingam SS; Sun SY
    Oncogene; 2021 Dec; 40(49):6653-6665. PubMed ID: 34635799
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib.
    Castellano GM; Aisner J; Burley SK; Vallat B; Yu HA; Pine SR; Ganesan S
    J Thorac Oncol; 2019 Nov; 14(11):1982-1988. PubMed ID: 31254668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor-mutant lung cancers.
    Gu J; Yao W; Shi P; Zhang G; Owonikoko TK; Ramalingam SS; Sun SY
    Cancer; 2020 Aug; 126(16):3788-3799. PubMed ID: 32497272
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer.
    Lee J; Kim HS; Lee B; Kim HK; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
    Cancer; 2020 Jun; 126(11):2704-2712. PubMed ID: 32154925
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis.
    Hirashima T; Satouchi M; Hida T; Nishio M; Kato T; Sakai H; Imamura F; Kiura K; Okamoto I; Kasahara K; Uchida H; Vowler SL; Mitsudomi T
    Cancer Sci; 2019 Sep; 110(9):2884-2893. PubMed ID: 31265163
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nanoparticles for co-delivery of osimertinib and selumetinib to overcome osimertinib-acquired resistance in non-small cell lung cancer.
    Chen W; Yu D; Sun SY; Li F
    Acta Biomater; 2021 Jul; 129():258-268. PubMed ID: 34048974
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disclosing Potential Therapeutic Targets Associated With Osimertinib Resistance in the Non-small Cell Lung Cancer Cell Line H1975.
    Tong X; Zhang R; Sun R; Yang W; Sun J; Chen J; Li F
    Anticancer Res; 2023 Dec; 43(12):5459-5474. PubMed ID: 38030186
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study.
    Takahama T; Azuma K; Shimokawa M; Takeda M; Ishii H; Kato T; Saito H; Daga H; Tsuboguchi Y; Okamoto I; Otsubo K; Akamatsu H; Teraoka S; Takahashi T; Ono A; Ohira T; Yokoyama T; Sakai K; Yamamoto N; Nishio K; Nakagawa K
    Cancer; 2020 Jan; 126(9):1940-1948. PubMed ID: 32022929
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of EGFR T790M mutation status following the development of Osimertinib resistance on the efficacy of Osimertinib in non-small cell lung cancer: A meta-analysis.
    Guo L; Zhou G; Huang M; Tang K; Xu J; Chen J
    Clin Respir J; 2024 Apr; 18(4):e13748. PubMed ID: 38584122
    [TBL] [Abstract][Full Text] [Related]  

  • 35. AXIN1/MYC Axis Mediated the Osimertinib Resistance in EGFR Mutant Non-Small Cell Lung Cancer Cells.
    Yu H; Wang Z; Dong Y; Li L; Fan X; Zheng N; Jiang J; Lin C; Lu C; Li K; Feng M
    Tohoku J Exp Med; 2024 May; 262(4):269-276. PubMed ID: 38233113
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DNA topoisomerase II inhibition potentiates osimertinib's therapeutic efficacy in EGFR-mutant non-small cell lung cancer models.
    Chen Z; Vallega KA; Wang D; Quan Z; Fan S; Wang Q; Leal T; Ramalingam SS; Sun SY
    J Clin Invest; 2024 Mar; 134(10):. PubMed ID: 38451729
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer.
    Papadimitrakopoulou VA; Han JY; Ahn MJ; Ramalingam SS; Delmonte A; Hsia TC; Laskin J; Kim SW; He Y; Tsai CM; Hida T; Maemondo M; Kato T; Jenkins S; Patel S; Huang X; Laus G; Markovets A; Thress KS; Wu YL; Mok T
    Cancer; 2020 Jan; 126(2):373-380. PubMed ID: 31769875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HOTAIR induces EGFR-TKIs resistance in non-small cell lung cancer through epithelial-mesenchymal transition.
    Wang Q; Li X; Ren S; Su C; Li C; Li W; Yu J; Cheng N; Zhou C
    Lung Cancer; 2020 Sep; 147():99-105. PubMed ID: 32683208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of nano-lipid formulation of CARP-1 mimetic, CFM-4.17 to improve systemic exposure and response in osimertinib resistant non-small cell lung cancer.
    Kommineni N; Nottingham E; Bagde A; Patel N; Rishi AK; Dev SRS; Singh M
    Eur J Pharm Biopharm; 2021 Jan; 158():172-184. PubMed ID: 33220423
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MET amplification results in heterogeneous responses to osimertinib in EGFR-mutant lung cancer treated with erlotinib.
    Nishiyama A; Takeuchi S; Adachi Y; Otani S; Tanimoto A; Sasaki M; Matsumoto S; Goto K; Yano S
    Cancer Sci; 2020 Oct; 111(10):3813-3823. PubMed ID: 32735723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.